#United States #New York #securities lawsuit #ClaimsFiler #Ultragenyx

Ultragenyx Investor Alert

In a significant development for those invested in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), ClaimsFiler, a free service dedicated to providing vital information for shareholders, is reminding investors who have faced losses exceeding $100,000 that they must file their lead plaintiff applications by April 6, 2026. This reminder comes in the wake of an ongoing class action lawsuit concerning the company, which has raised serious concerns regarding its disclosure practices.

Background of the Lawsuit

The class action lawsuit involves allegations against Ultragenyx and its executives for not revealing critical information that affected shareholders during the specified Class Period, which spans from August 3, 2023, to December 26, 2025. The legal proceedings are currently taking place in the United States District Court for the Southern District of New York.

Notably, on December 26, 2025, Ultragenyx reported the results of their Phase 3 clinical studies for setrusumab (UX143), aimed at treating Osteogenesis Imperfecta. Unfortunately, the studies reportedly failed to show a statistically significant reduction in fracture rates among patients. This announcement led to a drastic decline in the company's stock price, plummeting nearly 42% from $34.19 per share to $19.72 just a few days later. This drastic swing in stock price has prompted significant concern among investors, many of whom are now seeking legal recourse.

Investor Action

Investors who acquired Ultragenyx shares during the Class Period may qualify for participation in this class action. ClaimsFiler encourages these investors to visit their website and take necessary actions before the deadline. The service provides a platform where investors can access resources and assistance in filing claims effectively. Investors can also gain insights into their legal options by reaching out to the law firm Kahn Swick & Foti, LLC, known for handling securities class action claims.

For those seeking guidance, ClaimsFiler offers a comprehensive registration process where investors can upload their transaction data and receive updates related to ongoing litigation that affects their financial interests. This proactive approach ensures that retail investors do not miss out on potential recoveries linked to class action settlements.

Understanding the Implications

The situation surrounding Ultragenyx illustrates broader themes in the securities market, emphasizing the importance of transparency and timely disclosure from public companies. Regulatory compliance is non-negotiable, especially for firms engaged in clinical trials and biotech innovations that can witness rapid shifts in stock prices based on experimental outcomes.

As the legal proceedings progress, investors are strongly encouraged to stay informed about the developments of this case and their rights as shareholders. The outcome may set a significant precedent not only for Ultragenyx but for the entire biotechnology sector, especially related to transparency practices in clinical trials and investor communications.

In conclusion, if you're one of the investors who has suffered losses while investing in Ultragenyx, make sure to act promptly to secure your potential claims before the deadline. For further assistance, visit ClaimsFiler.com or call their toll-free number at (844) 367-9658. Time is of the essence, and your action could make a significant difference in your financial recovery during this uncertain time.